临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 2367004-54-2

XL092

CAS号:2367004-54-2
分子式: C29H25FN4O5 分子量: 528.53
产品形式: Free base
研发状态: Active not recruiting
研发用途: Neoplasm Malignant; Renal Cell Carcinoma; Hormone Receptor Positive Breast Carcinoma; Metastatic Castration-resistant Prostate Cancer; Colorectal Cancer
研究机构: Exelixis
研发日期: March 20 2019
研发阶段: Phase 1
XL092 (JUN04542) is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM, and 7.2 nM in cell-based assays, respectively.

CAS: 2364554-48-1

Aficamten (CK-274)

CAS号:2364554-48-1
分子式: C18H19N5O2 分子量: 337.38
产品形式: free base
研发状态: Recruiting
研发用途: Obstructive Hypertrophic Cardiomyopathy
研究机构: Ji Xing Pharmaceuticals (Shanghai) Co. Ltd.
研发日期: November 14 2023
研发阶段: Phase 3
Aficamten (CK-274, CK 3773274) is a novel cardiac myosin inhibitor that reduces myocardial contractility in vitro and in vivo with an IC50 of 1.4 μM.

CAS: 2359650-19-2

TPX-0046

CAS号:2359650-19-2
分子式: C21H21FN6O3 分子量: 424.43
产品形式: Free base
研发状态: Terminated
研发用途: Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET Gene Mutation; Metastatic Solid Tumor; Advanced Solid Tumor
研究机构: Turning Point Therapeutics Inc.
研发日期: December 6 2019
研发阶段: Phase 1 : Phase 2
TPX-0046 is a novel RET/SRC inhibitor with a mean IC50 of 17 nM for RETG810R in Ba/F3 cell proliferation assay.

CAS: 23541-50-6

Daunorubicin (RP 13057) HCl

中文名称:盐酸柔红霉素
CAS号:23541-50-6
分子式: C27H29NO10.HCl 分子量: 563.98
产品形式: Hydrochloride
研发状态: Completed
研发用途: Relapsed Pediatric ALL; Relapsed Pediatric AML; Refractory Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia
研究机构: Children''s Mercy Hospital Kansas City
研发日期: May 8 2020
研发阶段: Phase 2
Daunorubicin HCl (Daunomycin, RP 13057, Rubidomycin) inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis.

CAS: 2353-33-5

Decitabine (NSC 127716)

中文名称:地西他滨
CAS号:2353-33-5
分子式: C8H12N4O4 分子量: 228.21
产品形式: free base
研发状态: Not yet recruiting
研发用途: Healthy Volunteers
研究机构: Novo Nordisk A/S
研发日期: February 27 2024
研发阶段: Phase 1
Decitabine (Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR,NSC 127716) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

CAS: 2349386-89-4

Molnupiravir (EIDD-2801)

中文名称:((2R,3S,4R,5R)-3,4-二羟基-5-((Z)-4-(肟基)-2-氧代-3,4-二氢嘧啶-1(2H)-基)四氢呋喃-2-基)甲基异丁酸酯
CAS号:2349386-89-4
分子式: C13H19N3O7 分子量: 329.31
产品形式: Free Base
研发状态: Completed
研发用途: SARS-CoV 2
研究机构: Ridgeback Biotherapeutics LP; Merck Sharp & Dohme LLC
研发日期: June 16 2020
研发阶段: Phase 2
Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19.